Correlation Between Hospital Mater and Neurocrine Biosciences

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Hospital Mater and Neurocrine Biosciences at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Hospital Mater and Neurocrine Biosciences into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Hospital Mater Dei and Neurocrine Biosciences, you can compare the effects of market volatilities on Hospital Mater and Neurocrine Biosciences and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Hospital Mater with a short position of Neurocrine Biosciences. Check out your portfolio center. Please also check ongoing floating volatility patterns of Hospital Mater and Neurocrine Biosciences.

Diversification Opportunities for Hospital Mater and Neurocrine Biosciences

-0.33
  Correlation Coefficient

Very good diversification

The 3 months correlation between Hospital and Neurocrine is -0.33. Overlapping area represents the amount of risk that can be diversified away by holding Hospital Mater Dei and Neurocrine Biosciences in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Neurocrine Biosciences and Hospital Mater is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Hospital Mater Dei are associated (or correlated) with Neurocrine Biosciences. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Neurocrine Biosciences has no effect on the direction of Hospital Mater i.e., Hospital Mater and Neurocrine Biosciences go up and down completely randomly.

Pair Corralation between Hospital Mater and Neurocrine Biosciences

Assuming the 90 days trading horizon Hospital Mater Dei is expected to under-perform the Neurocrine Biosciences. In addition to that, Hospital Mater is 2.12 times more volatile than Neurocrine Biosciences. It trades about -0.07 of its total potential returns per unit of risk. Neurocrine Biosciences is currently generating about 0.47 per unit of volatility. If you would invest  3,490  in Neurocrine Biosciences on September 5, 2024 and sell it today you would earn a total of  374.00  from holding Neurocrine Biosciences or generate 10.72% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy95.24%
ValuesDaily Returns

Hospital Mater Dei  vs.  Neurocrine Biosciences

 Performance 
       Timeline  
Hospital Mater Dei 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Hospital Mater Dei has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
Neurocrine Biosciences 

Risk-Adjusted Performance

10 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Neurocrine Biosciences are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite somewhat uncertain fundamental drivers, Neurocrine Biosciences sustained solid returns over the last few months and may actually be approaching a breakup point.

Hospital Mater and Neurocrine Biosciences Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Hospital Mater and Neurocrine Biosciences

The main advantage of trading using opposite Hospital Mater and Neurocrine Biosciences positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Hospital Mater position performs unexpectedly, Neurocrine Biosciences can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neurocrine Biosciences will offset losses from the drop in Neurocrine Biosciences' long position.
The idea behind Hospital Mater Dei and Neurocrine Biosciences pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Other Complementary Tools

Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Equity Valuation
Check real value of public entities based on technical and fundamental data
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm